Total Payments
$542,214
2023 Payments
$171.41
Companies
51
Transactions
1,414
Medicare Patients
2,488
Medicare Billing
$243,540
Payment Breakdown by Category
Other$228,937 (42.2%)
Research$204,962 (37.8%)
Travel$41,495 (7.7%)
Consulting$34,218 (6.3%)
Food & Beverage$32,269 (6.0%)
Education$333.39 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $204,962 | 23 | 37.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $178,088 | 85 | 32.8% |
| Travel and Lodging | $41,495 | 159 | 7.7% |
| Consulting Fee | $34,218 | 15 | 6.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $33,250 | 11 | 6.1% |
| Food and Beverage | $32,269 | 1,108 | 6.0% |
| Honoraria | $17,600 | 6 | 3.2% |
| Education | $333.39 | 7 | 0.1% |
Payments by Type
General
$337,252
1,391 transactions
Research
$204,962
23 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch Health US, LLC | $149,167 | 6 | $0 (2018) |
| AbbVie Inc. | $90,059 | 282 | $0 (2021) |
| PFIZER INC. | $53,918 | 141 | $0 (2022) |
| Celgene Corporation | $51,958 | 95 | $0 (2019) |
| Eli Lilly and Company | $50,225 | 15 | $0 (2022) |
| Amgen Inc. | $30,828 | 91 | $0 (2021) |
| Valeant Pharmaceuticals North America LLC | $30,375 | 55 | $0 (2017) |
| Sun Pharmaceutical Industries Inc. | $22,013 | 60 | $0 (2022) |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $17,944 | 147 | $0 (2022) |
| Allergan Inc. | $8,981 | 21 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $171.41 | 7 | UCB, Inc. ($171.41) |
| 2022 | $1,928 | 6 | PFIZER INC. ($1,650) |
| 2021 | $43,001 | 238 | Amgen Inc. ($19,789) |
| 2020 | $25,602 | 200 | Amgen Inc. ($6,711) |
| 2019 | $119,138 | 319 | AbbVie, Inc. ($44,959) |
| 2018 | $247,185 | 289 | Bausch Health US, LLC ($149,167) |
| 2017 | $105,189 | 355 | Valeant Pharmaceuticals North America LLC ($30,375) |
All Payment Transactions
1,414 individual payment records from CMS Open Payments — Page 1 of 57
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/02/2023 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $22.76 | General |
| Category: Immunology | ||||||
| 07/27/2023 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $22.40 | General |
| Category: Immunology | ||||||
| 07/01/2023 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $25.16 | General |
| Category: Immunology | ||||||
| 05/10/2023 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $26.43 | General |
| Category: Immunology | ||||||
| 03/31/2023 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $13.99 | General |
| Category: Immunology | ||||||
| 02/10/2023 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $29.15 | General |
| Category: Immunology | ||||||
| 02/01/2023 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $31.52 | General |
| Category: Immunology | ||||||
| 11/22/2022 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $21.86 | General |
| Category: Immunology | ||||||
| 09/09/2022 | Eli Lilly and Company | — | — | In-kind items and services | $55.00 | Research |
| Study: A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | ||||||
| 05/11/2022 | Ortho Dermatologics, a division of Bausch Health US, LLC | RETIN-A (Drug) | Food and Beverage | In-kind items and services | $112.50 | General |
| Category: Dermatology | ||||||
| 03/21/2022 | PFIZER INC. | CIBINQO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Inflammation & Immunology | ||||||
| 02/04/2022 | Sun Pharmaceutical Industries Inc. | Absorica LD (Drug), Winlevi | Food and Beverage | In-kind items and services | $22.23 | General |
| Category: Dermatology | ||||||
| 02/03/2022 | Sun Pharmaceutical Industries Inc. | Absorica LD (Drug), Winlevi | Food and Beverage | In-kind items and services | $66.11 | General |
| Category: Dermatology | ||||||
| 12/22/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $12.84 | General |
| Category: IMMUNOLOGY | ||||||
| 12/22/2021 | AbbVie Inc. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $12.22 | General |
| Category: IMMUNOLOGY | ||||||
| 12/22/2021 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $2.99 | General |
| Category: Dermatology | ||||||
| 12/15/2021 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $31.30 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/15/2021 | Ortho Dermatologics, a division of Bausch Health US, LLC | JUBLIA (Drug), ARAZLO | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: Podiatry | ||||||
| 12/14/2021 | Kyowa Kirin, Inc. | POTELIGEO (Drug) | Food and Beverage | In-kind items and services | $21.36 | General |
| Category: MONOCLONAL ANTIBODY | ||||||
| 12/09/2021 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $26.44 | General |
| Category: Dermatology | ||||||
| 12/09/2021 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $0.80 | General |
| Category: Dermatology | ||||||
| 12/08/2021 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $87.48 | General |
| 12/07/2021 | AbbVie Inc. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: IMMUNOLOGY | ||||||
| 12/07/2021 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $14.90 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2021 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | Bausch Health US, LLC | $149,167 | 6 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $25,350 | 2 |
| A PHASE 2, MULTICENTER, RANDOMIZED, PARALLEL-ARM, PLACEBO- CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH MODERATE-TO- SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $9,320 | 2 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $8,714 | 3 |
| A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 | Eli Lilly and Company | $3,850 | 2 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | Valeant Pharmaceuticals North America LLC | $3,750 | 1 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris | Valeant Pharmaceuticals North America LLC | $1,820 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3375880 IN ADULT SUBJECTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: THE ADMIRE STUDY | Eli Lilly and Company | $1,599 | 1 |
| A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $946.79 | 3 |
| A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 | Eli Lilly and Company | $274.32 | 1 |
| A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $170.66 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 12 | 1,169 | 3,069 | $214,250 | $133,974 |
| 2020 | 12 | 1,319 | 2,991 | $196,270 | $109,566 |
Total Patients
2,488
Total Services
6,060
Medicare Billing
$243,540
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 570 | 1,168 | $115,135 | $75,959 | 66.0% |
| 17000 | Destruction of skin growth | Office | 2021 | 208 | 336 | $30,240 | $16,402 | 54.2% |
| 96900 | Application of ultraviolet light to skin | Office | 2021 | 11 | 691 | $17,275 | $13,149 | 76.1% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 82 | 103 | $15,375 | $8,843 | 57.5% |
| 11104 | Punch biopsy of single skin lesion | Office | 2021 | 35 | 38 | $6,650 | $4,083 | 61.4% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 49 | 49 | $6,860 | $3,236 | 47.2% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 123 | 589 | $8,835 | $2,983 | 33.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 22 | 22 | $4,290 | $2,798 | 65.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 27 | 27 | $3,375 | $2,451 | 72.6% |
| 11441 | Removal of growth (0.6 to 1.0 centimeters) of the face, ears, eyelids, nose, lips, or mouth | Office | 2021 | 11 | 11 | $2,200 | $1,657 | 75.3% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 20 | 23 | $2,875 | $1,602 | 55.7% |
| 11200 | Removal of up to and including 15 skin tags | Office | 2021 | 11 | 12 | $1,140 | $812.36 | 71.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 603 | 1,075 | $91,375 | $55,386 | 60.6% |
| 17000 | Destruction of skin growth | Office | 2020 | 251 | 380 | $34,200 | $16,977 | 49.6% |
| 96900 | Application of ultraviolet light to skin | Office | 2020 | 16 | 594 | $14,850 | $10,517 | 70.8% |
| 17110 | Destruction of up to 14 skin growths | Office | 2020 | 101 | 128 | $19,100 | $10,148 | 53.1% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 79 | 79 | $10,475 | $5,244 | 50.1% |
| 11104 | Punch biopsy of single skin lesion | Office | 2020 | 33 | 36 | $6,300 | $3,038 | 48.2% |
| 17003 | Destruction of 2-14 skin growths | Office | 2020 | 157 | 619 | $9,285 | $2,796 | 30.1% |
| 17262 | Destruction of malignant growth (1.1 to 2.0 centimeters) of trunk, arms, or legs | Office | 2020 | 12 | 12 | $2,400 | $1,828 | 76.2% |
| 11401 | Removal of growth (0.6 to 1.0 centimeters) of the trunk, arms, or legs | Office | 2020 | 11 | 11 | $1,980 | $1,287 | 65.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 27 | 27 | $3,375 | $1,105 | 32.7% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2020 | 14 | 15 | $1,955 | $902.94 | 46.2% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 15 | 15 | $975.00 | $336.66 | 34.5% |
About Dr. Ellen Frankel, M.D
Dr. Ellen Frankel, M.D is a Procedural Dermatology healthcare provider based in Cranston, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/13/2005. The National Provider Identifier (NPI) number assigned to this provider is 1053306423.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ellen Frankel, M.D has received a total of $542,214 in payments from pharmaceutical and medical device companies, with $171.41 received in 2023. These payments were reported across 1,414 transactions from 51 companies. The most common payment nature is "" ($204,962).
As a Medicare-enrolled provider, Frankel has provided services to 2,488 Medicare beneficiaries, totaling 6,060 services with total Medicare billing of $243,540. Data is available for 2 years (2020–2021), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Procedural Dermatology
- Location Cranston, RI
- Active Since 09/13/2005
- Last Updated 09/29/2011
- Taxonomy Code 207NS0135X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1053306423
Products in Payments
- Otezla (Drug) $78,201
- EUCRISA (Drug) $50,685
- Humira (Biological) $41,776
- Skyrizi (Biological) $32,812
- SILIQ (Drug) $21,597
- ILUMYA (tildrakizumab-asmn) injection (Biological) $15,884
- ONEXTON (Drug) $9,713
- JUBLIA (Drug) $6,879
- ESKATA (Drug) $6,230
- SKYRIZI (Biological) $6,126
- HUMIRA (Biological) $4,127
- ACZONE (Drug) $3,918
- ILUMYA (Biological) $3,463
- Otezla (Biological) $3,390
- Seysara (Drug) $3,002
- SEYSARA (Drug) $2,657
- ELIDEL (Drug) $2,442
- EPIDUO FORTE (Drug) $2,089
- Tremfya (Drug) $1,740
- CIBINQO (Drug) $1,650
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.